American Academy of Family Physicians
About UsNews & PublicationsMembersCME CenterClinical & ResearchPractice MgmtPolicy & AdvocacyCareers

Acute Coronary Syndrome

Coronary artery disease is the leading cause of death in the United States. Acute coronary syndrome is a medical emergency that complicates coronary artery disease. This edition of FP EssentialsTM will address four advances in the management of acute coronary syndrome: management of ST-segment elevation myocardial infarction (MI); management of non-ST-segment elevation MI; management of unstable angina; and outpatient recommendations and follow-up after acute coronary syndrome.

The FP EssentialsTM monograph should be approximately 10,000 words in length, divided into four sections of approximately 2,500 words each, plus a preface, key practice recommendations, a maximum of 15 tables and figures, recommended readings, and references. The monograph should focus on what’s new in each topic and should answer the key questions listed for each section. Each section should begin with an illustrative case, similar to the examples provided, with modifications to emphasize key points. The references listed below include information that should be considered in preparation of this edition of FP EssentialsTM. However, these references are only a useful starting point that should be used to identify additional information to review.

Section One: Advances in the Management of ST-Segment Elevation Myocardial Infarction

Example case: Michael is a 60-year-old white man with a history of smoking, diabetes, hypertension, and hyperlipidemia, who developed crushing chest pressure while eating dinner. He was transported to the emergency department, where an electrocardiogram revealed 3-mm ST-segment elevations in leads V2 through V4. He was taken to the cardiac catheterization department where a 95% occlusion of the mid-left anterior descending artery was identified, which responded well to angioplasty and coronary stent placement.

Key questions to consider:
  • What are the recommended first-line drugs for patients presenting with an ST-segment elevation myocardial infarction (STEMI)?
  • What is the role of primary percutaneous coronary intervention (PCI) in STEMI?
  • What is the role of coronary stenting in STEMI? If a coronary stent is placed, is there any benefit of drug-eluting stents over bare metal stents?
  • What is the role of fibrinolytic therapy in hospitals without PCI capability?
  • When should patients be transferred to hospitals that can perform PCI?
  • What is the role of prehospital fibrinolytic therapy?
  • When should facilitated PCI-using regimens other than full-dose fibrinolytic therapy be considered?
  • When should rescue PCI after fibrinolytic therapy be considered?
  • Is anticoagulation therapy recommended? If so, what agents are recommended and for what duration?
  • What agents are recommended for patients with a history of heparin-induced thrombocytopenia?
  • Should clopidogrel (Plavix) be added to acetylsalicylic acid (aspirin) in patients with STEMI? If so, when should therapy be initiated, and at what dose (high-dose or low-dose)?
Initial references to consider:
  • Singh S, Bahekar A, Molnar J, et al. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Clin Cardiol. 2009;32(7):358-364.
  • Loomba RS, Arora R. ST elevation myocardial infarction guidelines today: a systematic review exploring updated ACC/AHA STEMI guidelines and their applications. Am J Ther. 2009 Jun 13. [Epub ahead of print]
  • Verheugt FW. Acute myocardial infarction associated with ST segment elevation and the new European Society of Cardiology guidelines. Heart. 2009;95(13):1112-1117.
  • Wailoo AJ, Goodacre S, Sampson F, et al. Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty Project. Heart. 2009 Jun 8. [Epub ahead of print]
  • Huynh T, Perron S, O’Loughlin J, et al. Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: bayesian hierarchical meta-analyses of randomized controlled trials and observational studies. Circulation. 2009;119(24):3101-3109.
  • Brar SS, Leon MB, Stone GW, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53(18):1677-1689.
  • Piscione F, Piccolo R, Cassese S, et al. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials. Catheter Cardiovasc Interv. 2009;74(2):323-332.
  • Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 2009;30(4):459-468.
  • Welsh RC, Travers A, Huynh T, et al. Canadian Cardiovascular Society Working Group: Providing a perspective on the 2007 focused update of the American College of Cardiology and American Heart Association 2004 guidelines for the management of ST elevation myocardial infarction. Can J Cardiol. 2009;25(1):25-32.
  • Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296-329.
  • Cantor WJ, Fitchett D, Borgundvaag B, et al; TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705-2718.

Section Two: Advances in the Management of Non-ST-Segment Elevation Myocardial Infarction

Example case: Alice is a 50-year-old woman with hypertension and diabetes who presents to the emergency department with 3 hours of severe indigestion and nausea. She is hemodynamically stable, and results of the physical examination are normal. The electrocardiogram reveals 1 mm flat ST depressions with T wave inversions in leads II, III, and aVF. Laboratory results are remarkable for a troponin I that is elevated to 0.7 ng/mL.

Key questions to consider:
  • What are the initial drugs recommended for patients admitted with a non-ST-segment elevation myocardial infarction (NSTEMI)?
  • Is anticoagulation therapy recommended? If so, what agents are recommended, and for what duration?
  • When is early invasive therapy preferable to an initial conservative (noninvasive) strategy?
  • What is the role of glycoprotein IIb/IIIa inhibitor therapy in NSTEMI?
  • Should clopidogrel (Plavix) be added to acetylsalicylic acid (aspirin) in patients with NSTEMI? If so, when should therapy be initiated, and at what dose (high-dose or low-dose)?
  • For patients found to have significant coronary stenosis by coronary angiogram, which should be treated with PCI, and which fair better with a coronary artery bypass graft?
  • Is there a role for magnetocardiography in the early detection of NSTEMI?
  • Is there a role for 80-lead electrocardiogram for detection of ST-segment elevation in patients suspected to have an NSTEMI?
  • What is the prognostic value of serum biomarkers after NSTEMI?
Initial references to consider:
  • Lim HK, Kim K, Lee YH, et al. Detection of non-ST-elevation myocardial infarction using magnetocardiogram: New information from spatiotemporal electrical activation map. Ann Med. 2009:1-14.
  • Eggers KM, Lagerqvist B, Venge P, et al. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2009;54(4):357-364.
  • Seyfarth M, Kastrati A, Mann JF, et al. Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. Am J Kidney Dis. 2009 Jul 8. [Epub ahead of print]
  • Rogowski W, Burch J, Palmer S, et al. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess. 2009;13(31):iii-iv, ix-xi, 1-77.
  • Chan MY, Sun JL, Newby LK, et al. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation. 2009;119(24):3110-3117. Erratum in: Circulation. 2009;120(4):e28.
  • Alexander JH, Becker RC, Bhatt DL, et al; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877-2885.
  • Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009;4(6):1032-1043.
  • Sculpher MJ, Lozano-Ortega G, Sambrook J, et al. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J. 2009;157(5):845-852.
  • Nicolau JC, Cohen M, Montalescot G. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes. J Cardiovasc Pharmacol. 2009;53(6):440-445.
  • Slattery D, Pollack CV Jr. Does timing matter? Upstream or downstream administration of antiplatelet therapy. Am J Emerg Med. 2009;27(3):348-361 [Review].
  • Swahn E, Alfredsson J, AfzalR, et al. Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. Eur Heart J. 2009 Feb 7. [Epub ahead of print]
  • Riezebos RK, Ronner E, Ter Bals E, et al; OPTIMA Trial. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. Heart. 2009;95(10):807-812.
  • Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol. 2008; 52(24):2046-2099.
  • Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157. Erratum in: J Am Coll Cardiol. 2008;51(9):974.

Section Three: Advances in the Management of Unstable Angina

Example case: Susan is a 60-year-old black woman with a history of stable angina who has been experiencing more frequent episodes of angina at lower levels of exertion. She usually develops substernal pressure, which is relieved with inactivity, after walking 10 blocks. Over the past 3 days, she has noticed that she develops more severe chest pressure with shortness of breath after walking 20 yards. She presents to your office for evaluation. An electrocardiogram at rest reveals a normal sinus rhythm, a heart rate of 80 bpm, and nonspecific ST-segment elevation and T-wave changes.

Key questions to consider:
  • What are the initial drugs recommended for patients admitted to the hospital with unstable angina?
  • When is early invasive therapy preferable to an initial conservative (noninvasive) strategy in unstable angina?
  • How are patients classified as having high-risk versus low-risk unstable angina?
  • Should clopidogrel (Plavix) be added to acetylsalicylic acid (aspirin) in patients with unstable angina? If so, when should therapy be initiated, and at what dose (high-dose or low-dose)?
Initial references to consider:
  • Eggers KM, Lagerqvist B, Venge P, et al. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2009;54(4):357-364.
  • Rogowski W, Burch J, Palmer S, et al. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess. 2009;13(31):iii-iv, ix-xi, 1-77.
  • Sculpher MJ, Lozano-Ortega G, Sambrook J, et al. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J. 2009;157(5):845-852.
  • Nicolau JC, Cohen M, Montalescot G. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes. J Cardiovasc Pharmacol. 2009;53(6):440-445.
  • Swahn E, Alfredsson J, AfzalR, et al. Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. Eur Heart J. 2009 Feb 7. [Epub ahead of print]
  • Riezebos RK, Ronner E, Ter Bals E, et al; OPTIMA Trial. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. Heart. 2009;95(10):807-812.
  • Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157. Erratum in: J Am Coll Cardiol. 2008;51(9):974.
  • Spinler SA. Managing acute coronary syndrome: evidence-based approaches. Am J Health Syst Pharm. 2007;64(11 Suppl 7):S14-S24.
  • Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2549-2569 [Review].
  • Oliveira GB, Avezum A, Anderson FA Jr, et al; GRACE Investigators. Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. Am Heart J. 2007;153(4):493-499.

Section Four: Outpatient Recommendations and Follow-Up After Acute Coronary Syndrome

Example case: Jeremiah is a 50-year-old white man with a history of diabetes and hypertension who was admitted to the hospital with a non-ST-segment elevation myocardial infarction (NSTEMI). He underwent percutaneous coronary intervention with a drug-eluting stent placed in the first diagonal artery. He has done well post-revascularization and is ready for discharge. He asks you what he can expect for follow-up of his condition over the next 6 months.

Key questions to consider:
  • What activity restrictions are required for patients who have undergone treatment for acute coronary syndrome?
  • What lifestyle modification is advised for patients who required hospitalization for acute coronary syndrome?
  • How long should antiplatelet therapy be continued in patients with bare metal and drug-eluting stents, and in those without stents? Are there situations in which antiplatelet therapy should be stopped early?
  • Which drugs are beneficial for secondary prevention of cardiovascular events?
  • Which nonpharmacologic interventions are beneficial for secondary prevention of cardiovascular events?
  • How frequently should patients undergo evaluation in the office after an acute coronary syndrome event?
  • After an acute coronary syndrome event, are serum biomarkers of prognostic utility?
  • For patients who have had an acute coronary syndrome event, is follow-up noninvasive cardiac testing (eg, exercise or dobutamine echocardiogram, or a treadmill or pharmacologic thallium stress test) necessary, and, if so, when should this be performed?
  • When is it safe to resume driving, sexual activity, or athletics after treatment of an acute coronary syndrome event?
Initial references to consider:
  • Scirica BM, Cannon CP, Sabatine MS, et al; PROVE IT-TIMI 22 Investigators. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009;55(2):265-273.
  • Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157. Erratum in: J Am Coll Cardiol. 2008;51(9):974.
Shop Catalog